Abstract:Background Conventional clinical detection methods such as CT, urine cytology, and ureteroscopy display low sensitivity and/or are invasive in the diagnosis of upper tract urinary carcinoma (UTUC), a factor precluding their use. Previous studies on urine biopsy have not shown satisfactory sensitivity and specificity in the application of both gene mutation or gene methylation panels. Therefore, these unfavorable factors call for an urgent need for a sensitive and non-invasive method for the diagnosis of UTUC. Methods In this study, a total of 161 hematuria patients were enrolled with (n = 69) or without (n = 92) UTUC. High-throughput sequencing of 17 genes and methylation analysis for ONECUT2 CpG sites were combined as a liquid biopsy test panel. Further, a logistic regression prediction model that contained several significant features was used to evaluate the risk of UTUC in these patients. Results In total, 86 UTUC− and 64 UTUC+ case samples were enrolled for the analysis. A logistic regression analysis of significant features including age, the mutation status of TERT promoter, and ONECUT2 methylation level resulted in an optimal model with a sensitivity of 94.0%, a specificity of 93.1%, the positive predictive value of 92.2% and a negative predictive value of 94.7%. Notably, the area under the curve (AUC) was 0.957 in the training dataset while internal validation produced an AUC of 0.962. It is worth noting that during follow-up, a patient diagnosed with ureteral inflammation at the time of diagnosis exhibiting both positive mutation and methylation test results was diagnosed with ureteral carcinoma 17 months after his enrollment. Conclusion This work utilized the epigenetic biomarker ONECUT2 for the first time in the detection of UTUC and discovered its superior performance. To improve its sensitivity, we combined the biomarker with high-throughput sequencing of 17 genes test. It was found that the selected logistic regression model diagnosed with ureteral cancer can evaluate upper tract urinary carcinoma risk of patients with hematuria and outperform other existing panels in providing clinical recommendations for the diagnosis of UTUC. Moreover, its high negative predictive value is conducive to rule to exclude patients without UTUC.

Rapid screening for genitourinary cancers: mass spectrometry-based metabolic fingerprinting of urine

Bladder cancer biomarker screening based on non-targeted urine metabolomics

Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery

Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS

Smartphone-Based Fluorescent Profiling of Quaternary MicroRNAs in Urine for Rapid Diagnosis of Urological Cancers Using a Multiplexed Isothermal Exponential Amplification Reaction

Rapid Detection of Volatile Organic Metabolites in Urine by High-Pressure Photoionization Mass Spectrometry for Breast Cancer Screening: A Pilot Study

Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics

Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry.

Hollow Core-Shell Metal Oxide Heterojunctions for the Urinary Metabolic Fingerprint-Based Noninvasive Diagnostic Strategy.

A Characteristic Biosignature For Discrimination Of Gastric Cancer From Healthy Population By High Throughput Gc-Ms Analysis

Methylation-based biomarkers for early detection of urological cancer

Developing Urinary Metabolomic Signatures As Early Bladder Cancer Diagnostic Markers

Study on Urinary Metabonmics Using Rapid Resolution Liquid Chromatography Tandem Mass Spectrometry

Urine Metabolic Profiling for Rapid Lung Cancer Screening: A Strategy Combining Rh-Doped SrTiO3-Assisted Laser Desorption/Ionization Mass Spectrometry and Machine Learning

Enhanced Detection of Genitourinary Cancers Using Fragmentation and Copy Number Profiles Obtained from Urinary Cell-Free DNA

Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome

Applying fragmentomics profiles of urinary cell-free DNA for bladder cancer detection.

LC-MS based urine untargeted metabolomic analyses to identify and urothelial cancer

A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma

Fast Quantitative Urinary Proteomic Profiling Workflow for Biomarker Discovery in Kidney Cancer

Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry